Showing 1 posts of 1 posts found.
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement